FRANKFURT: Bayer AG’s new chief executive officer (CEO) is weighing a breakup of the pharma and agriculture conglomerate, a move that may undo much of the legacy of his predecessor, including the troubled acquisition of Monsanto.
Bill Anderson, who took over as CEO in June from Werner Baumann, said he may separate Bayer’s consumer-health or crop-science operations.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
